

Please try another search
By Christiana Sciaudone
Investing.com -- Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)fell 2.6% and Sanofi (PA:SASY)fell 1.7% in after-hours trading Thursday after the companies said phase 3 of their Covid-19 vaccine trial did not meet endpoints and they would halt the U.S. trial.
Kevzara (sarilumab) 400 mg did not meet primary and key secondary endpoints compared to a placebo. Minor positive trends were seen but were not statistically significant, and countered by negative trends in a subgroup of critical patients.
A trial of patients who received a dose of 800 mg of Kevzara was also halted.
A separate Sanofi-led trial outside the U.S. in hospitalized patients with severe and critical Covid-19 using a different dosing regimen is ongoing.
By Hyunjoo Jin and Akash Sriram (Reuters) - Tesla (NASDAQ:TSLA) Inc delivered 17.9% fewer electric vehicles in the second quarter from the previous quarter, as China's COVID...
MADRID (Reuters) - Spain-based cabin crew at Ryanair plan to strike for 12 days this month to demand better working conditions, the USO (NYSE:USO) and SICTPLA unions said on...
Tesla (NASDAQ:TSLA) said it delivered 254,695 electric vehicles (EVs) in the second quarter, an increase of 27% on a year-to-year basis. Still, the reported number came below the...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.